Biomarkers predicting tumor response and evasion to anti-angiogenic therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 86-100

  Jahangiri, Arman ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Biomarkers; Cancer; Evasion

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CRIZOTINIB; EPHEDRINE; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; PLACENTAL GROWTH FACTOR; PLX 40032; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER TISSUE; CLINICAL RESEARCH; COLORECTAL CANCER; DISEASE MARKER; DRUG COST; DRUG RESPONSE; ENDOTHELIUM CELL; EXPERIMENTAL ANIMAL; GENETIC MARKER; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; IMAGING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; TREATMENT FAILURE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; GENETIC MARKERS; HUMANS; NEOPLASMS; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 82155203054     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.10.004     Document Type: Review

References (85)

1. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
2. De Gruttola V.G., Clax P., DeMets D.L., Downing G.J., Ellenberg S.S., Friedman L., Gail M.H., Prentice R., Wittes J., Zeger S.L. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control. Clin. Trials 2001, 22:485-502.
3. Extended interview: Janet Woodcock discusses cancer biomarkers, PBS News Hour, vol. 2011, 2007.
4. Clark A.J., Lamborn K.R., Butowski N.A., Chang S.M., Prados M.D., Clarke J.L., McDermott M.W., Parsa A.T., Berger M.S., Aghi M.K. Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment. Neurosurgery 2011.
5. Westphal J.R., Ruiter D.J., De Waal R.M.W. Anti-angiogenic treatment of human cancer: Pitfalls and promises. Int. J. Cancer 2000, 86:870-873.
6. Schmidt C. Costly cancer drugs trigger proposals to modify clinical trial design. J. Natl. Cancer Inst. 2009, 101:1662-1664.
7. Sinha G. Expensive cancer drugs with modest benefit ignite debate over solutions. J. Natl. Cancer Inst. 2008, 100:1347-1349.
8. van't Veer L.J., Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452:564-570.
9. Clark A.J., Butowski N.A., Chang S.M., Prados M.D., Clarke J., Polley M.Y., Sughrue M.E., McDermott M.W., Parsa A.T., Berger M.S., Aghi M.K. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg. 2010, 114(6):1609-1616.
10. Rose S.D., Aghi M.K. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Clin. Neurosurg. 2010, 57:123-128.
11. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., Fleisher M., Lilja H., Brogi E., Boyd J., Sanchez-Carbayo M., Holland E.C., Cordon-Cardo C., Scher H.I., Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116:271-284.
12. Timms J.F., Cramer R., Camuzeaux S., Tiss A., Smith C., Burford B., Nouretdinov I., Devetyarov D., Gentry-Maharaj A., Ford J., Luo Z., Gammerman A., Menon U., Jacobs I. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin. Chem. 2010, 56:262-271.
13. Demetri G.D., Heinrich M.C., Fletcher J.A., Fletcher C.D., Van den Abbeele A.D., Corless C.L., Antonescu C.R., George S., Morgan J.A., Chen M.H., Bello C.L., Huang X., Cohen D.P., Baum C.M., Maki R.G. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin. Cancer Res. 2009, 15:5902-5909.
14. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
15. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
16. Batchelor T.T., Duda D.G., di Tomaso E., Ancukiewicz M., Plotkin S.R., Gerstner E., Eichler A.F., Drappatz J., Hochberg F.H., Benner T., Louis D.N., Cohen K.S., Chea H., Exarhopoulos A., Loeffler J.S., Moses M.A., Ivy P., Sorensen A.G., Wen P.Y., Jain R.K. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28:2817-2823.
17. Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., Stroiakovski D., Thatcher N., Tsai C.M., Wu Y.L., Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010, 11:733-740.
18. Dincer M., Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann. Pharmacother. 2006, 40:2278-2279.
19. Rini B.I., Schiller J.H., Fruehauf J.P., Cohen E.E., Tarazi J.C., Rosbrook B., Ricart A.D., Olszanski A.J., Kim S., Spano J. Association of diastolic blood pressure (dBP) >= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J. Clin. Oncol. 2008, 26:3543. (Meeting Abstracts).
20. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., Flockhart D.A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E.A., Cobleigh M., Shenkier T., Edgerton S., Miller K.D. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26:4672-4678.
21. Hurwitz H., Douglas P.S., Middleton J.P., Sledge G.W., Johnson D.H., Reardon D.A., Chen D., Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab. American Society of Clinical Oncology Annual Meeting, Chicago, IL 2010.
22. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., Atkins J.N., Picus J., Czaykowski P., Dutcher J., Small E.J. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010, 28:2137-2143.
23. Burstein H.J., Chen Y.H., Parker L.M., Savoie J., Younger J., Kuter I., Ryan P.D., Garber J.E., Chen H., Campos S.M., Shulman L.N., Harris L.N., Gelman R., Winer E.P. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 2008, 14:7871-7877.
24. Hanrahan E.O., Ryan A.J., Mann H., Kennedy S.J., Langmuir P., Natale R.B., Herbst R.S., Johnson B.E., Heymach J.V. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 2009, 15:3600-3609.
25. Bass M.B., Sherman S.I., Schlumberger M.J., Davis M.T., Kivman L., Khoo H.M., Notari K.H., Peach M., Hei Y.J., Patterson S.D. Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer. J. Clin. Endocrinol. Metab. 2010, 95(11):5018-5027.
26. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., Kabbinavar F., Holden S.N., Novotny W.F., Frantz G.D., Hillan K.J., Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006, 24:217-227.
27. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., Kim S.T., Chen I., George D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26:3743-3748.
28. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D.V., Lahdenranta J., Chung D.C., Fischman A.J., Lauwers G.Y., Shellito P., Czito B.G., Wong T.Z., Paulson E., Poleski M., Vujaskovic Z., Bentley R., Chen H.X., Clark J.W., Jain R.K. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 2009, 27:3020-3026.
29. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 2008, 14:1407-1412.
30. Kelly R.J., Rajan A., Force J., Keen C., Cao L., Yu Y., Choyke P.L., Turkbey B., Raffeld M., Xi L., Steinberg S.M., Wright J.J., Lopez-Chavez A., Kummar S., Guttierrez M., Giaccone G. Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Clin. Cancer Res. 2011, 17(5):1190-1199.
31. Lu J.F., Bruno R., Eppler S., Novotny W., Lum B., Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 2008, 62:779-786.
32. Loupakis F., Falcone A., Masi G., Fioravanti A., Kerbel R.S., Del Tacca M., Bocci G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J. Clin. Oncol. 2007, 25:1816-1818.
33. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
34. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van Steenkiste C., Tugues S., Rolny C., De Mol M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van Bergen T., Cuervo H., Xiao W.H., Le Henaff C., Buysschaert I., Kharabi Masouleh B., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jimenez W., Noel A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P., Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van Vlierberghe H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2011, 141:178-190.
35. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Kolumam G., Vernes J.M., Eastham-Anderson J., Haughney P., Kowanetz M., Hagenbeek T., Kasman I., Reslan H.B., Ross J., Van Bruggen N., Carano R.A., Meng Y.J., Hongo J.A., Stephan J.P., Shibuya M., Ferrara N. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2011, 141:166-177.
36. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., Sindhwani V., Blaszkowsky L.S., Yoon S.S., Lahdenranta J., Bhargava P., Meyerhardt J., Clark J.W., Kwak E.L., Hezel A.F., Miksad R., Abrams T.A., Enzinger P.C., Fuchs C.S., Ryan D.P., Jain R.K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27:3027-3035.
37. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., Harder J., Blum H., Robertson J., Jurgensmeier J.M., Puchalski T.A., Young H., Saunders O., Unger C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25:3045-3054.
38. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:16-24.
39. Bagley R.G., Ren Y., Weber W., Yao M., Kurtzberg L., Pinckney J., Bangari D., Nguyen C., Brondyk W., Kaplan J., Teicher B.A. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin. Cancer Res. 2011, 17:976-988.
40. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., Folkman J., Bello C., Baum C., DePrimo S.E., Shalinsky D.R., Demetri G.D., Heymach J.V. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007, 13:2643-2650.
41. Deprimo S.E., Bello C.L., Smeraglia J., Baum C.M., Spinella D., Rini B.I., Michaelson M.D., Motzer R.J. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007, 5:32.
42. Saltz L.B., Rosen L.S., Marshall J.L., Belt R.J., Hurwitz H.I., Eckhardt S.G., Bergsland E.K., Haller D.G., Lockhart A.C., Rocha Lima C.M., Huang X., DePrimo S.E., Chow-Maneval E., Chao R.C., Lenz H.J. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 2007, 25:4793-4799.
43. George D.J., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Margolin K., Hutson T.E., Rini B.I. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. J. Clin. Oncol. 2007, 25:5035. (Meeting Abstracts).
44. van de Stolpe A., van der Saag P.T. Intercellular adhesion molecule-1. J. Mol. Med. (Berl.) 1996, 74:13-33.
45. Miyamoto K., Khosrof S., Bursell S.E., Moromizato Y., Aiello L.P., Ogura Y., Adamis A.P. Vascular endothelial growth factor. Am. J. Pathol. 2000, 156:1733-1739.
46. Gerstner E.R., Eichler A.F., Plotkin S.R., Drappatz J., Doyle C.L., Xu L., Duda D.G., Wen P.Y., Jain R.K., Batchelor T.T. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol 2010, 103(2):325-332.
47. Bidard F.C., Mathiot C., Degeorges A., Etienne-Grimaldi M.C., Delva R., Pivot X., Veyret C., Bergougnoux L., de Cremoux P., Milano G., Pierga J.Y. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann. Oncol. 2010, 21:1765-1771.
48. Goon P.K., Boos C.J., Stonelake P.S., Blann A.D., Lip G.Y. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb. Haemost. 2006, 96:45-52.
49. Newman J.R., Helman E.E., Safavy S., Zhang W., Rosenthal E.L. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett. 2009, 274:313-318.
50. Myers A.L., Williams R.F., Ng C.Y., Hartwich J.E., Davidoff A.M. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J. Pediatr. Surg. 2010, 45:1080-1085.
51. Karp J.E., Gojo I., Pili R., Gocke C.D., Greer J., Guo C., Qian D., Morris L., Tidwell M., Chen H., Zwiebel J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 2004, 10:3577-3585.
52. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 2008, 26:271-278.
53. Swanton C., Larkin J.M., Gerlinger M., Eklund A.C., Howell M., Stamp G., Downward J., Gore M., Futreal P.A., Escudier B., Andre F., Albiges L., Beuselinck B., Oudard S., Hoffmann J., Gyorffy B., Torrance C.J., Boehme K.A., Volkmer H., Toschi L., Nicke B., Beck M., Szallasi Z. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2010, 2:53.
54. Fountzilas G., Kourea H.P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., Papazisis K.T., Timotheadou E., Efstratiou I., Koutras A., Pentheroudakis G., Christodoulou C., Aravantinos G., Miliaras D., Petraki K., Papandreou C.N., Papakostas P., Bafaloukos D., Repana D., Razis E., Pectasides D., Dimopoulos A.M. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the hellenic cooperative oncology group experience with biological marker evaluation. Anticancer Res. 2011, 31:3007-3018.
55. Wilson P.M., Yang D., Shi M.M., Zhang W., Jacques C., Barrett J.C., Daneneberg K., Trarbach T., Folprecht G., Meinhardt G., Lenz H.J. Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2 2008, vol. 26:4002. American Society of Clinical Oncology, Chicago, IL.
56. Ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., Hurwitz H.I., Kabbinavar F., Novotny W.F., Hillan K.J., Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst. 2005, 97:981-989.
57. Hasselbalch B., Eriksen J.G., Broholm H., Christensen I.J., Grunnet K., Horsman M.R., Poulsen H.S., Stockhausen M.T., Lassen U. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010, 118:585-594.
58. Schultheis A.M., Lurje G., Rhodes K.E., Zhang W., Yang D., Garcia A.A., Morgan R., Gandara D., Scudder S., Oza A., Hirte H., Fleming G., Roman L., Lenz H.J. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 2008, 14:7554-7563.
59. Gordon M.A., Gil J., Lu B., Zhang W., Yang D., Yun J., Schneider S., Groshen S., Iqbal S., Press O.A., Rhodes K., Lenz H.J. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006, 7:67-88.
60. Lurje G., Zhang W., Schultheis A.M., Yang D., Groshen S., Hendifar A.E., Husain H., Gordon M.A., Nagashima F., Chang H.M., Lenz H.J. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 2008, 19:1734-1741.
61. Koutras A., Antonacopoulou A., Fostira F., Briasoulis E.C., Sgouros I., Koumarianou A., Xiros N., Christodoulou C., Fountzilas G., Kalofonos H. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. American Society of Clinical Oncology Annual Meeting, Chicago, IL 2010.
62. Chen W., Delaloye S., Silverman D.H., Geist C., Czernin J., Sayre J., Satyamurthy N., Pope W., Lai A., Phelps M.E., Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 2007, 25:4714-4721.
63. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., Kambadakone A.R., Muzikansky A., Zheng H., Clark J.W., Abrams T.A., Chan J.A., Enzinger P.C., Bhargava P., Kwak E.L., Allen J.N., Jain S.R., Stuart K., Horgan K., Sheehan S., Fuchs C.S., Ryan D.P., Sahani D.V. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010, 11:48-54.
64. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
65. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D.D., Friedman A.H., Friedman H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13:1253-1259.
66. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:4722-4729.
67. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
68. Aghi M., Cohen K.S., Klein R.J., Scadden D.T., Chiocca E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006, 66:9054-9064.
69. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., Adinin R., Overman M.J., Valero V., Wen S., Lieu C., Yan S., Tran H.T., Ellis L.M., Abbruzzese J.L., Heymach J.V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28:453-459.
70. Montesano R., Vassalli J.D., Baird A., Guillemin R., Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:7297-7301.
71. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
72. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., Lynch M.P., Rueda B.R., Chung D.C. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
73. Hu D.E., Hori Y., Fan T.P. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993, 17:135-143.
74. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6742-6747.
75. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., Ho C., Ross J., Tan M., Carano R.A., Meng Y.G., Ferrara N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
76. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
77. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2640-2645.
78. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., Venner P., Knox J.J., Chi K.N., Kollmannsberger C., McDermott D.F., Oh W.K., Atkins M.B., Bukowski R.M., Rini B.I., Choueiri T.K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27:5794-5799.
79. Jain R., Scarpace L.M., Ellika S., Torcuator R., Schultz L.R., Hearshen D., Mikkelsen T. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J. Neurooncol 2010, 96:423-431.
80. Gerstner E.R., Frosch M.P., Batchelor T.T. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol. 2010, 28:e91-93.
81. Wasik M.A., Zhang Q., Marzec M., Kasprzycka M., Wang H.Y., Liu X. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin. Oncol. 2009, 36:S27-S35.
82. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Janne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
83. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
84. U.S. National Library of Medicine, Bethesda (MD). Accessed October 14, 2011. http://www.clinicaltrials.gov.
85. Pepe M.S., Feng Z., Janes H., Bossuyt P.M., Potter J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 2008, 100:1432-1438.